Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CiplaLUX:CIPLA 82 3-Year EBITDA Growth Rate is 7.20% as of Jun. 2026, which is 45% below its 10-year median of 13.00. GuruFocus rates LUX:CIPLA with a GF Score™ of 82/100 and a GF Value™ of $19.19. The stock has 6 warning signs investors should review. Among 810 Drug Manufacturers companies, Cipla ranks worse than 52.84% on this metric.
During the past 12 months, Cipla's average EBITDA Per Share Growth Rate was -28.20% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 7.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 11.10% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 11.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cipla was 24.60% per year. The lowest was 1.80% per year. And the median was 13.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Cipla 3-Year EBITDA Growth Rate Related Terms
LUX:CIPLA vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cipla's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cipla 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cipla's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Cipla's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 7.20% mean?
Cipla (LUX:CIPLA) has a 3-Year EBITDA Growth Rate of 7.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cipla and its competitors. This is 45% below median its historical median of 13.00. Over the past decade, Cipla's 3-Year EBITDA Growth Rate has ranged from 1.80 to 24.60. According to the industry distribution chart, Cipla ranks #428 out of 810 companies in the Drug Manufacturers industry, placing it in the top 52.8%.
Is Cipla's 3-Year EBITDA Growth Rate too high?
Cipla's current 3-Year EBITDA Growth Rate of 7.20% is 45% below median its 10-year median of 13.00. Over the past 10 years, this metric has ranged from a low of 1.80 to a high of 24.60. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.85. Cipla's value of 7.20% is 18.6% below this industry median. Based on the distribution chart, Cipla ranks #428 out of 810 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cipla has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Cipla's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cipla ranks #428 out of 810 companies for 3-Year EBITDA Growth Rate. This places Cipla in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.85. Cipla's value of 7.20% is 18.6% below this benchmark. Historically, Cipla's own 3-Year EBITDA Growth Rate has ranged from 1.80 to 24.60 over the past decade. While the company's 10-year median is 13.00 vs. the industry median of 8.85, Cipla has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.85, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cipla's current 3-Year EBITDA Growth Rate of 7.20% is 18.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cipla and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cipla's current 3-Year EBITDA Growth Rate is 7.20%, which is 45% below median its own 10-year median of 13.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipla stock overvalued right now?
Cipla (LUX:CIPLA) has a current 3-Year EBITDA Growth Rate of 7.20%. The stock's GF Value™ is $19.19, compared to a current price of $18.10 — trading 5.7% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 7.20%, which is 45% below median its 10-year median of 13.00 and 18.6% below the Drug Manufacturers industry median of 8.85. Cipla's overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Cipla (LUX:CIPLA), the current 3-Year EBITDA Growth Rate is 7.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cipla (LUX:CIPLA) Overvalued in 2026?
Based on GuruFocus' analysis, Cipla stock appears to be undervalued.
The current stock price of $18.10 is trading 5.7% below its estimated GF Value™ of $19.19.
Key valuation signals for LUX:CIPLA:
3-Year EBITDA Growth Rate: 7.20% (45% below median its 10-year median of 13.00)
GF Value™: $19.19 vs. price of $18.10 (5.7% below fair value)
Industry Position: 18.6% below the Drug Manufacturers median (#428 of 810)
No single metric tells the full story. See the LUX:CIPLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
82GF Score
Get the complete analysis for LUX:CIPLA
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUX:CIPLA has been successfully added to your 
